Get the Stockscreener App
18.73
1.96%
-0.3785
Adma Biologics Inc stock is traded at $18.73, with a volume of 997.98K.
It is down -1.96% in the last 24 hours and down -7.66% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$19.11
Open:
$19.08
24h Volume:
997.98K
Relative Volume:
0.20
Market Cap:
$4.38B
Revenue:
$330.24M
Net Income/Loss:
$34.79M
P/E Ratio:
-93.66
EPS:
-0.2
Net Cash Flow:
$66.12M
1W Performance:
+12.12%
1M Performance:
-7.66%
6M Performance:
+175.11%
1Y Performance:
+413.29%
1-Day Range:
$18.57
$19.25
1-Week Range:
$16.09
$20.18
52-Week Range:
$3.54
$21.13
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Vanguard Group Inc's Strategic Acquisition in ADMA Biologics Inc - GuruFocus.com
Did ADMA Biologics Commit Securities Fraud Resulting in 20% Stock Drop? Contact BFA Law about its Ongoing Securities Fraud Investigation (Nasdaq:ADMA) - AccessWire
ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. - MarketBeat
ADMA Biologics jumps as KPMG becomes new auditor - MSN
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle - MSN
BFA Law is Investigating ADMA BIOLOGICS for Securities - GlobeNewswire
BFA Law is Investigating ADMA BIOLOGICS for Securities Fraud after Stock Plummets 20%; Contact the Firm if You Suffered Losses (Nasdaq:ADMA) - GlobeNewswire Inc.
ADMA Biologics stock jumps after naming auditor (ADMA:NASDAQ) - Seeking Alpha
ADMA Biologics (NASDAQ:ADMA) Shares Gap UpTime to Buy? - MarketBeat
ADMA INVESTIGATION NOTE: Contact BFA Law about ADMA Biologics Securities Fraud Investigation into Auditor Resignation (Nasdaq:ADMA) - AccessWire
Rice Hall James & Associates LLC Cuts Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA Biologics appoints KPMG as new auditor - Investing.com India
ADMA Biologics (ADMA) to Release Quarterly Earnings on Thursday - MarketBeat
Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Declines By 5.9% - MarketBeat
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? - Zacks Investment Research
Louisiana State Employees Retirement System Makes New $2.25 Million Investment in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire
ADMA INVESTIGATION NOTICE: ADMA Biologics Stock Plummets - GlobeNewswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages ADMA Biologics Inc (ADMA) Shareholders to Inquire about Securities Investigation - AccessWire
ADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics Investors - GlobeNewswire
PFG Investments LLC Has $4.42 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Trading (ADMA) With Integrated Risk Controls - Stock Traders Daily
Assenagon Asset Management S.A. Raises Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
ADMA INVESTOR ALERT: ADMA Biologics Investors that Suffered Losses are Alerted to Contact BFA Law about Securities Fraud Investigation into Auditor Resignation (Nasdaq:ADMA) - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages ADMA Biologics Inc (ADMA) Stockholders to Inquire about Securities Investigation - AccessWire
Bragar Eagel & Squire, P.C. Is Investigating ADMA - GlobeNewswire
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages ADMA Biologics Inc (ADMA) Investors to Inquire about Securities Investigation - AccessWire
ADMA INVESTIGATION UPDATE: ADMA Biologics Investors are - GlobeNewswire
ADMA INVESTIGATION NOTICE: ADMA Biologics, Inc. Investors are Alerted of Ongoing Securities Fraud Investigation after Stock Drops 20%; Contact BFA Law for Information - AccessWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
ADMA FRAUD UPDATE: ADMA Biologics, Inc. Investors are Notified to Contact BFA Law about the Securities Fraud Investigation after Auditor Resignation (Nasdaq:ADMA) - AccessWire
State Street Corp's Strategic Acquisition of ADMA Biologics Shares - Yahoo Finance
State Street Corp's Strategic Acquisition of ADMA Biologics Shar - GuruFocus.com
ADMA Biologics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses - GlobeNewswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm - Kilgore News Herald
ADMA FRAUD ALERT: BFA Law Alerts ADMA Biologics, Inc. Investors to Contact the Firm about its Investigation into the Company after Auditor Resigns - AccessWire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADMA Biologics Inc (ADMA) And Encourages Investors to Reach Out - AccessWire
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on - The Bakersfield Californian
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
(ADMA) Long Term Investment Analysis - Stock Traders Daily
ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock? - MSN
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc - EIN News
Why I'm Expecting a Price Bounce Back for ADMA - TheStreet
ADMA LEGAL NOTICE: ADMA Biologics, Inc. is being - GlobeNewswire
ADMA Biologics shares maintain buy rating despite auditor change By Investing.com - Investing.com Canada
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? - Yahoo Finance
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Guiheen Lawrence P. | Director |
Sep 09 '24 |
Sale |
18.47 |
9,000 |
166,189 |
153,941 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):